1.00Open1.00Pre Close0 Volume15 Open Interest7.50Strike Price0.00Turnover336.52%IV73.47%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry1.00Extrinsic Value100Contract SizeAmericanOptions Type0.4765Delta0.0943Gamma4.90Leverage Ratio-0.0357Theta0.0009Rho2.33Eff Leverage0.0050Vega
Champions Oncology Stock Discussion
Champions Oncology Reports Quarterly Revenue of $14.0 Million
Champions Oncology (Nasdaq: CSBR) reported its financial results for Q4 and fiscal year 2024.
Q4 revenue increased 7% to $14 million, with an adjusted EBITDA income of $884,000.
However, annual revenue decreased 7% to $50.2 million, with a fiscal year 2024 adjusted EBITDA loss of $3.9 million.
The company faced challenges due to the biotech sector's funding environment and pharmaceutical spending p...
Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development
Champions Oncology (CSBR) announced a strategic collaboration with Medicines Discovery Catapult (MDC) to boost the development of radiopharmaceutical therapeutics. This partnership leverages Champions' patient-derived models and pharmacology solutions with MDC's radiochemistry and multi-modal imaging expertise. The collaboration aims...
No comment yet